Carmot Therapeutics has filed to go public in a chilly environment for new listings, but the obesity biotech’s place in one of drug development’s hottest fields could buoy its chances of a successful IPO.
The Berkeley, CA-based biotech plans to debut on Nasdaq as $CRMO before year’s end, according to…
Click here to view original post
